Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Change in Account Payables: 2009-2025

Historic Change in Account Payables for Myriad Genetics (MYGN) over the last 15 years, with Sep 2025 value amounting to -$800,000.

  • Myriad Genetics' Change in Account Payables rose 77.78% to -$800,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 million, marking a year-over-year decrease of 1800.00%. This contributed to the annual value of $4.7 million for FY2024, which is 227.03% up from last year.
  • According to the latest figures from Q3 2025, Myriad Genetics' Change in Account Payables is -$800,000, which was down 122.22% from $3.6 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Change in Account Payables ranged from a high of $14.0 million in Q4 2021 and a low of -$12.9 million during Q3 2021.
  • In the last 3 years, Myriad Genetics' Change in Account Payables had a median value of $1.1 million in 2023 and averaged $380,000.
  • Its Change in Account Payables has fluctuated over the past 5 years, first surged by 1,266.67% in 2021, then tumbled by 1,166.67% in 2022.
  • Over the past 5 years, Myriad Genetics' Change in Account Payables (Quarterly) stood at $14.0 million in 2021, then tumbled by 117.14% to -$2.4 million in 2022, then slumped by 145.83% to -$5.9 million in 2023, then surged by 81.36% to -$1.1 million in 2024, then soared by 77.78% to -$800,000 in 2025.
  • Its Change in Account Payables stands at -$800,000 for Q3 2025, versus $3.6 million for Q2 2025 and -$1.1 million for Q4 2024.